Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer

• Material Type: 博士論文
• Title: Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
• Author/Editor: Takaoka, Toshi; Kimura, Tetsuo; Shimoyama, Rai; Kawamoto, Shunji; Sakamoto, Kazuki; Goda, Fuminori; Miyamoto, Hiroshi; Negoro, Yuji; Tsuji, Akihito; Yoshizaki, Koji; Goji, Takahiro; Kitamura, Shinji; Yano, Hiromi; Okamoto, Koichi; Kimura, Masako; Okahisa, Toshiya; Muguruma, Naoki; Niitsu, Yoshiro; Takayama, Tetsuji
• Author Heading: Takaoka, Toshi; Kimura, Tetsuo; Shimoyama, Rai; Kawamoto, Shunji; Sakamoto, Kazuki; Goda, Fuminori; Miyamoto, Hiroshi; Negoro, Yuji; Tsuji, Akihito; Yoshizaki, Koji; Goji, Takahiro; Kitamura, Shinji; Yano, Hiromi; Okamoto, Koichi; Kimura, Masako; Okahisa, Toshiya; Muguruma, Naoki; Niitsu, Yoshiro; Takayama, Tetsuji
• Publication, Distribution, etc.: Springer Berlin Heidelberg
• Publication Date: 2016-06-24
• Publication Date (W3CDTF): 2016-06-24
• Alternative Title: 転移性大腸癌に対する2次治療としてのIRIS+panitumumab療法の有効性の検討; IRIS plus panitumumab for metastatic CRC
• Periodical title: Cancer Chemotherapy and Pharmacology
• No. or year of volume/issue: 78 2
• Volume: 78
• Issue: 2
• Pages: 397-403
• ISSN (Periodical Title): ISSN : 0344-5704; ISSN : 1432-0843
• Degree grantor/type: 徳島大学
• Date Granted: 2016-10-27
• Dissertation Number: 甲第2997号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: colorectal cancer; IRIS; panitumumab; second-line therapy; chemotherapy; irinotecan; S-1
• Target Audience: 一般
• Note (General): Background Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients. However, the combination of IRIS plus an anti-EGFR agent has not been evaluated previously. This study aimed to investigate the feasibility and efficacy of IRIS with panitumumab as second-line therapy for wild-type KRAS mCRC. Methods Main inclusion criteria were patients with wild-type KRAS mCRC refractory to one prior chemotherapy regimen for mCRC, ECOG PS 0-2, and age ≥ 20 years. Patients received panitumumab (6mg/kg) and irinotecan (100mg/m2) on days 1 and 15 and S-1 (40-60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks. The primary endpoint was the feasibility of the therapy. The secondary endpoints were response rate (RR), progression-free survival (PFS), and overall survival (OS). Results A total of 36 patients received protocol treatment in eight centers. Of these, 23 patients (63.9%) completed protocol treatment, demonstrating achievement of the primary endpoint. The most frequent grade 3/4 toxicities were diarrhea (16.7%), acne-like rash (13.9%), and neutropenia (11.1%). The overall RR was 33.3% (12/36). Of these 4 five underwent conversion surgery. Median PFS and OS were 9.5 months (95% CI 3.5-15.4 months) and 20.1 months (95% CI 16.7-23.2 months), respectively. Conclusion IRIS plus panitumumab has an acceptable toxicity profile and a promising efficacy in patients with previously treated wild-type KRAS mCRC. Accordingly, this regimen can be an additional treatment option for second-line chemotherapy in wild-type KRAS mCRC.
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Rights (production): The final publication is available at link.springer.com.
• Related Material (DOI): 10.1007/s00280-016-3096-5
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 徳島大学 : 徳島大学機関リポジトリ

Table of Contents

https://repo.lib.tokushima-u.ac.jp/files/public/10/109985/20170929143235884588/LID201701051002.pdf fulltext

https://repo.lib.tokushima-u.ac.jp/files/public/10/109985/20190423161858420483/k2997_fulltext.pdf fulltext